With COVID cases on the rise in many countries, the race to find an effective vaccine is becoming a more pressing concern ...
Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
Flu season approaches and there's a new COVID variant. The time to act is now, or soon, according to the two largest local ...
A summer wave of cases locally and across the country may be on the decline and a vaccine targeting the latest variants is ...
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial ...